13th Pharmacovigilance conference

Follow
Verify
From Verify.Wiki
Jump to: navigation, search

Conference Aim

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

13th Pharmacovigilance 2017 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.  The entire program will cover the detection, analysis and prevention of adverse drug reactions.  It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pv requirements, and to improve their organizations' compliance with pv requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue.

Date

27th & 28th September 2017

Conference Venue

Hotel Holiday Inn Chicago O’Hare, USA, Chicago, USA

Conference Link

http://www.virtueinsight.com/pharma/13th-Pharmacovigilance-2017/

Conference Information

The Global Pharmacovigilance Market expected to Reach US$6.1 bn by 2020 expanding at a CAGR of 14.2% from 2015 to 2020 and also expected to reach a market size of $8.23 billion by 2022.

Medicinal products changed the way in which diseases are achieved and controlled in the current era of medical technology. Regardless of the benefits, Adverse Drug Reactions (ADRs) continue to rise leading to illness, disability and even death of the patients. Globally, ADRs are one of the leading causes of mortality. Monitoring and evaluation of drug safety becomes vital in order to enhance public health, which requires a (PV) system in place. Globalization and free trade explosion have changed the way individuals today access medicinal products. Therefore, effective collaboration is required between pharmaceutical organizations and the key pv players in order to minimize the risks associated with the use of medicines. By 2020, the size of the global pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey. The rapid induction in the market throws up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base. Along with clinical trials Bioavailability and bioequivalence studies also plays major role in clinical research. The global market for Biopharmaceuticsin 2013 was $305.1 million, which is expected to reach about $326.3 million by year-end 2014. The projected PAT instrumentation market is expected to be valued at around $450.6 million by 2019 at a compound annual growth rate (CAGR) of 6.7% for the period of 2014 to 2019.

13th Annual Pharmacovigilance 2017 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pv requirements, and to improve their organizations' compliance with pv requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. What does the future hold for pv? Find out at our conference on opportunities and activities shaping pv to 2020 with respect to regulations, technologies and services. Learn and know on what are drug producers and service providers doing? What regulations and technologies influence the current pv field? You can also discover at 13th Pharmacovigilance 2017 on spending forecasts for pv (US, the EU and Asia).

It gives me great pleasure in welcoming all of you to the Virtue Insight’s 13th Pharmacovigilance 2017. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.

Key Speakers

  • FATEMEH NOURI. E, Postdoctoral Fellow, FDA
  • ·GERSON PELTZ, Senior Director - Oncology Safety Risk Lead, Pfizer
  • MELVA T. COVINGTON, Senior Director, Head of Field Based Medical Strategy, Sanofi
  • DEEPA ARORA, Vice President - Pharmacovigilance & Global Head- Drug Safety & Risk Management, Lupin (India)
  • ·KHAUDEJA BANO, Senior Medical Director, Medical Device Safety Head, Abbvie
  • ·CARMIT STRAUSS, Global Risk Management Scientist / Safety Management – GPS, Amgen
  • BRUCE DONZANTI, Senior Group Director, Regulatory Pharmacovigilance Policy, Genentech
  • BRIAN DREYFUS, Director, Bristol-Myers Squibb
  • ·FAUZIA ANWAR, Director Global Pharmacovigilance and Risk Management, Roche
  • ·BEN LOCWIN, Director, Global R&D, Biogen (& President, Healthcare Science Advisors)
  • REEMA MEHTA, Senior Director, Head of Risk Management Center of Excellence, Pfizer
  • ·ESTHER DE LA CUESTA, Senior Medical Director, Pharmacovigilance, Takeda Pharmaceuticals
  • ·PHILLIP EICHORN, Senior Director (Worldwide Safety and Regulatory), Pfizer
  • ·ANKA G. EHRHARDT, Director Clinical Cytometry, Biomarker Technologies, ECTR, Bristol-Myers Squibb
  • ·BARBARA DA SILVA-TILLMANN, Senior Medical Director, Abbvie
  • ·CLAUDIO CARINI, Global Head of Clin. Immunology & Biomarkers, Pfizer
  • ·GEORGE VAN BAELEN, Head Pharmacovigilance Latin America & Carribean, Shire
  • SHELLY GOODMAN, Head, Global Pharmacovigilance, Portola Pharmaceuticals
  • ·SHEETAL KHEDKAR, Senior Director, Regulatory Science, Sarah Cannon Development Innovations

ROBERT S. WALSH, Consultant, Walsh Medical Consulting

Conference Booking Details

Super Early Discounted Pricing (valid till 4th June 17) : £700 Per Delegates

Super Early Discounted Pricing (valid till 4th June 17) : £1400 (3 Delegates at price of 2) for 3 Delegates

You can simply email and book your conference delegate seats

Conference Sponsor & Exhibition Space – Should you wish to Sponsor, or purchase a Exhibition Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to info@virtueinsight.com

Verification history